Quantum BioPharma Ltd. Research and Development Expense
Quantum BioPharma Ltd. (QNTM) reported Research and Development Expense of $2.76 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-26
- Quantum BioPharma Ltd. research and development expense for the quarter ending 2025-12-31 was $70.40K, a 98.36% decline year-over-year.
- Quantum BioPharma Ltd. research and development expense for the quarter ending 2025-09-30 was $495.22K, a 33.51% decline year-over-year.
- Quantum BioPharma Ltd. research and development expense for the quarter ending 2025-06-30 was $549.20K, a 38.84% decline year-over-year.
- Quantum BioPharma Ltd. research and development expense for the quarter ending 2025-03-31 was $1.65M, a 928.55% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $70.40K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $565.63K derived: sum of 2 quarters · filed 2026-03-26 | $1.11M derived: sum of 3 quarters · filed 2026-03-26 | $2.76M 20-F · filed 2026-03-26 |
| 2025-09-30 | $495.22K 6-K · filed 2025-11-06 | $1.04M derived: sum of 2 quarters · filed 2025-11-06 | $2.69M 6-K · filed 2025-11-06 | $6.97M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $549.20K 6-K · filed 2025-08-07 | $2.20M 6-K · filed 2025-08-07 | $6.48M derived: sum of 3 quarters · filed 2026-03-26 | $7.22M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $1.65M 6-K/A · filed 2025-06-16 | $5.93M derived: sum of 2 quarters · filed 2026-03-26 | $6.67M derived: sum of 3 quarters · filed 2026-03-26 | $7.57M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $4.28M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $5.03M derived: sum of 2 quarters · filed 2026-03-26 | $5.92M derived: sum of 3 quarters · filed 2026-03-26 | $6.08M 20-F · filed 2026-03-26 |
| 2024-09-30 | $744.80K 6-K · filed 2025-11-06 | $1.64M derived: sum of 2 quarters · filed 2025-11-06 | $1.80M 6-K · filed 2025-11-06 | $1.77M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $897.99K 6-K · filed 2025-08-07 | $1.06M 6-K · filed 2025-08-07 | $1.03M derived: sum of 3 quarters · filed 2026-03-26 | $1.06M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $160.26K 6-K/A · filed 2025-06-16 | $130.30K derived: sum of 2 quarters · filed 2026-03-26 | $163.28K derived: sum of 3 quarters · filed 2026-03-26 | $1.77M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | -$29.96K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $3.02K derived: sum of 2 quarters · filed 2026-03-26 | $1.61M derived: sum of 3 quarters · filed 2026-03-26 | $3.86M 20-F · filed 2026-03-26 |
| 2023-09-30 | $32.98K 6-K · filed 2024-11-12 | $1.64M derived: sum of 2 quarters · filed 2024-11-12 | $3.89M 6-K · filed 2024-11-12 | |
| 2023-06-30 | $1.61M 6-K/A · filed 2024-08-19 | $3.92M 6-K/A · filed 2024-08-19 | ||
| 2022-12-31 | $6.91M 20-F/A · filed 2025-03-31 | |||
| 2021-12-31 | $6.33M 20-F · filed 2024-04-02 | |||
| 2020-12-31 | $7.83M 20-F · filed 2023-03-31 | |||
| 2019-12-31 | $0.00 20-F · filed 2022-03-31 |